Business Medical Dialogues
    • facebook
    • twitter
    Sign in Signup
    • facebook
    • twitter
    Sign in Signup
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    Sign InRegister
    Business Medical Dialogues
    Sign inRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • SUGAM registration...

    SUGAM registration Mandatory: CDSCO directs State drugs controllers to enforce rule

    Meghna A SinghaniaBy Meghna A SinghaniaPublished On 2019-01-31T12:46:03+05:30  |  Updated On 2021-08-13T16:53:15+05:30

    New Delhi: Through a recent notice, Central Drugs Standard Control Organization informed all drug controllers about online SUGAM registration becoming compulsory for various licences granted for manufacture for sale or distribution of drugs, directing them to take necessary action in this regard


    This follows the recent amendment that was made by the Ministry of Health and Family Welfare to the Drugs and Cosmetics Rules, 1945 by inserting Rule 84AB - Information to be uploaded by the licensee on online portal SUGAM.


    As per the inserted rule, all the licensee shall register with portal SUGAM (www.cdscoonline.gov.in) and upload information, as per the format provided in the said portal, pertaining to the licences granted for manufacture for sale or distribution of drugs and the information so provided shall be updated from time to time and such information uploaded by the licensee shall be verified by the concerned Licensing Authority.


    With its release in the gazette notification, the rule is not effective from January 10 2019.


    The CDSCO has directed all the State Drugs Controllers to take necessary action and direct all the manufacturers to upload the data on SUGAM portal regarding the subject. The move will strengthen the drug regulatory system by way of improving the transparency, accountability as well as accessibility of the drugs in the country, the direction added


    Further, the state drug controllers have also been directed to verify the data uploaded by the manufacturers for compliance of the provisions of the rules. In case of any technical issues, one may email to it-helpdesk@cdsco.nic.in or contact IT cell at CDSCO headquarter, the notice added.


    In this regard, CDSCO has recently launched a module under SUGAM portal for uploading the data for this purpose. in this regard, CDSCO has also developed a user Manual (https://cdscoonline.gov.in/CDSCO/resources/app srv/cdsco/global/helpfiles/Manufacturer sign up.pdf ) which will provide the applicant with a step by step procedure for uploading the data.


    The e-governance solution, SUGAM was launched in the year 2015. This online portal enables online submission of applications requesting for permissions related to drugs, clinical trials, ethics committee, medical devices, vaccines and cosmetics. The system also builds up the database of approved drugs, manufacturers & formulations, retailers & wholesalers in India.


    Also Read: Application for Bulk Vaccine to be filed mandatorily through SUGAM: CDSCO

    application CDSCO Drug Controller drug manufacturing facilities Drugs and Cosmetics Rules Drugs and Cosmetics Rules 1945 drugs data e-Governance govt of india Indian government IT cell cdsco it-helpdesk@cdsco.nic.in Ministry of Health and Family Welfare online portal public notice Sugam Sugam news www.cdscoonline.gov.in 

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society petition

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society...

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Pharmaceuticals safe in PET packaging: High-level committee

      Pharmaceuticals safe in PET packaging: High-level committee

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Top priority on Delivery of Medicines through Speed Post: Minister

      Top priority on Delivery of Medicines through Speed Post: Minister

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 29 March 2022 11:15 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X